Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04362865|
Recruitment Status : Recruiting
First Posted : April 27, 2020
Last Update Posted : June 23, 2020
People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. Researchers think the risk may be related to how a person s B and T cells respond to the virus. B and T cells are the major components of a person s immune response. B and T cells responding to the virus with a favorable pattern may lead to recovery, and this favorable pattern may be helpful to establish. If people in a vaccine trial get this same favorable pattern when responding to a vaccine, this may be a useful early signal that the vaccine will be successful.
To examine how immune cells respond to COVID-19 infection.
Adults ages 18 and older who have a confirmed or suspected COVID-19 infection or had COVID-19 in the past.
Also, healthy donors with no suspected COVID-19 infection
Participants will be screened with medical record review.
Participants will be tested with a research assay to determine who was infected with COVID-19 and who was not. This test will be used to understand research results, not to advise patients.
Participants with active infection must be isolated, usually in a hospital.
Other participants may give blood samples at NIH or at their local doctor s office or lab.
Participants may give blood samples up to three times a week for a total of ten times, and may also give blood samples after starting a vaccine trial.
Participants will be contacted by phone or email every 2 months for up to 2 years.
|Condition or disease|
- Patients infected with COVID-19 have an unpredictable risk to worsen and die, making it difficult to decide who can quarantine at home and who should be monitored for respiratory failure as an inpatient. This risk may be related in part to the patient s immune response which can be characterized with respect to the B- and T-cell repertoire. Determining patterns of immune response which correlate with clinically effective immunity may help in determining risk.
- Patients receiving a vaccine for COVID-19 are tested for antibody production, but ultimately protection from infection and survival are the most important endpoints, which will take time. If patients can be checked for a pre-defined favorable pattern of immune response, it may significantly speed selection of effective candidate vaccines.
- In patients with hematologic malignancies, including patients with hairy cell leukemia (HCL) who we have extensive experience treating, we do not know if we should be steering away more from treatments which harm B-cell immunity, like rituximab or obinutuzumab, or steering away more from treatments which harm T-cell immunity, like purine analogs. Characterizing the immune response in COVID-19 patients will quickly answer this question.
- To characterize immune response in patients with current or prior COVID-19 infection
- Age 18 years or older
- Patients with known or suspected COVID-19 infection, or normal donors (i.e., those individuals without COVID-19)
- Blood and urine samples will be collected for research to characterize immune response.
- In individuals with known current or prior COVID-19, samples will be obtained up to every three days but no more than 10 times overall during the acute phase of infection and after recovery. In individuals without COVID-19 at the time of enrollment (i.e., normal donors), samples will be collected once; in the case of future COVID-19 infection, samples may be collected at the same times during/post-infection as an individual with COVID-19 at enrollment.
- All subjects will be followed for approximately 2 years. An additional blood sample may be collected in all subjects at one additional time after the receipt of future COVID-19- related vaccination.
- This protocol does not involve treatment. The accrual ceiling is set at 150 subjects.
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection|
|Actual Study Start Date :||April 27, 2020|
|Estimated Primary Completion Date :||December 1, 2023|
|Estimated Study Completion Date :||December 1, 2024|
Patients with confirmed or suspected COVID-19 infections
No COVID-19 infection
Patients without confirmed or suspected COVID-19 infections (i.e., normal donors)
- Characterize immune response [ Time Frame: Ongoing ]characterize immune response in patients with active or prior COVID-19 infection
- B- and T-cell arm immune response [ Time Frame: Ongoing ]determine if the B- or T-cell arm of the immune response is more active in responding to COVID-19 infection
- Immune response and outcome [ Time Frame: Ongoing ]determine if there is a correlation between the pattern of immune response to COVID-19 and outcome in patients with acute or resolved infection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04362865
|Contact: Monica E Epstein, R.N.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|Principal Investigator:||Robert J Kreitman, M.D.||National Cancer Institute (NCI)|